Please login to the form below

Not currently logged in
Email:
Password:

acute coronary syndrome

This page shows the latest acute coronary syndrome news and features for those working in and with pharma, biotech and healthcare.

AstraZeneca’s Farxiga scores another FDA fast-track designation

AstraZeneca’s Farxiga scores another FDA fast-track designation

or cardiovascular death in adult following an acute myocardial infarction or heart attack. ... In addition to Farxiga, AZ also has Brilinta (ticagrelor) in its cardiovascular, renal and metabolism (CVRM) franchise, which is approved for the treatment of

Latest news

  • AstraZeneca’s Brilinta reduces rate of secondary stroke AstraZeneca’s Brilinta reduces rate of secondary stroke

    The drug is already approved for the treatment of acute coronary syndrome (ACS) and for the secondary prevention of cardiovascular events among high-risk patients who have experienced a heart attack. ... who have previously experienced an acute ischaemic

  • AZ says Brilinta hits the mark in new stroke trial AZ says Brilinta hits the mark in new stroke trial

    Results of the phase 3 THALES trial showed Brilinta, in combination with aspirin, improved outcomes in patients who had experienced a minor acute ischaemic stroke or high-risk transient ischaemic attack. ... The drug is already approved for the treatment

  • AZ unveils phase 3 Brilinta data in CAD and type 2 diabetes AZ unveils phase 3 Brilinta data in CAD and type 2 diabetes

    In addition, the drug also demonstrated a 15% relative risk reduction in patients who had previously undergone a percutaneous coronary intervention (PCI), a procedure to open a blocked or narrowed coronary ... Brilinta is already  approved to reduce the

  • AZ says Brilinta hits the mark in diabetic heart disease AZ says Brilinta hits the mark in diabetic heart disease

    territory. Meanwhile, next year, AZ is also expecting a phase 3 readout in the THALES trial of Brilinta as a treatment for in acute ischemic stroke and transient ischaemic attack, that ... patients undergoing interventions for acute coronary syndrome (ACS

  • Cancer drugs and China sustain AZ’s return to growth Cancer drugs and China sustain AZ’s return to growth

    antiplatelet drug Brilinta (ticagrelor) rose 22% to $1.32bn thanks to continued market penetration in the treatment of acute coronary syndrome (ACS) and high-risk post-myocardial infarction patients.

More from news
Approximately 7 fully matching, plus 52 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • AZ names Brilique lead in Spain AZ names Brilique lead in Spain

    In this role Gribble will be responsible for the company's marketing of Brilique (ticagrelor) for acute coronary syndrome, including management, development and market access activities, and he will also be ... to save the lives of thousands of people

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Understanding the "Big Picture"

    A good example would be in acute coronary syndrome (ACS) where there is data to suggest that approximately 350, 000 males in the USA currently suffer from this syndrome.

More from PMHub
Approximately 1 fully matching, plus 0 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Mednet Group

Communique Small consultancy of the year 2020. With diversity and inclusion at our core, Mednet Group consists of Attigo CIC...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Infographics